Acrivon acquires JAK1 inhibitor ACR-525 and preclinical program from Aqilion
ACRV•Acrivon Therapeutics acquired Phase 2-ready oral JAK1 inhibitor ACR-525 and a preclinical PKC theta inhibitor program from Aqilion for undisclosed cash consideration, with no future royalty or milestone obligations.
1. Acquisition details
Acrivon Therapeutics acquired Aqilion’s Phase 2-ready oral JAK1 inhibitor ACR-525 and preclinical PKC theta inhibitor program for undisclosed cash consideration, with no future royalty or milestone obligations. The deal establishes immunology and inflammation as a strategic pillar alongside oncology; eosinophilic esophagitis is the first targeted indication for ACR-525, using a formulation designed for patients with difficulty swallowing.
